Emerging role of m6A methylation modification in ovarian cancer

Cancer Cell International

Xia-Qing Xu¹  Lin-Lin Chang²  Bao-Xia He²  Wen-Zhou Zhang²  Yan-Nan Fan²  Xue-Ling Liu²  Qian-Qian Guo² 

[1] Department of Clinical Pharmacy, Zhengzhou Central Hospital Affiliated To Zhengzhou University, Zhengzhou, China;Department of Pharmacy, Affiliated Tumour Hospital of Zhengzhou University, Henan Cancer Hospital, 127# Dongming Rd, 450008, Zhengzhou, Henan, China;

关键词: m6A modification;    Methyltransferase;    Demethylase;    RNA binding protein;    OC;   

DOI  :  10.1186/s12935-021-02371-3

来源: Springer

【 摘 要 】

m6A (N6-methyladenosine) methylation, a well-known modification in tumour epigenetics, dynamically and reversibly fine tunes the entire process of RNA metabolism. Aberrant levels of m6A and its regulators, which can predict the survival and outcomes of cancer patients, are involved in tumorigenesis, metastasis and resistance. Ovarian cancer (OC) ranks first among gynaecological tumours in the causes of death. At first diagnosis, patients with OC are usually at advanced stages owing to a lack of early biomarkers and effective targets. After treatment, patients with OC often develop drug resistance. This article reviews the recent experimental advances in understanding the role of m6A modification in OC, raising the possibility to treat m6A modification and its regulators as promising diagnostic markers and therapeutic targets for OC.Graphical Abstract

【 授权许可】

CC BY